首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 生物科技 > 生物仿製藥市場報告及預測：美國市場（2011∼2020年）
產業/市場分類
生物科技 (1574)
分子標靶治療學 (131)
生技設備 (354)
生物材料 (53)
生物標記 (155)
以基因為基之藥物開發 (202)
再生醫學 (119)
抗體和免疫 (189)
個人化醫學 (51)
基因治療學和RNAi (102)
市場調查報告書

生物仿製藥市場報告及預測：美國市場（2011∼2020年）

Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)

出版商 IMARC Group
出版日期 2011年10月 商品編碼 219015
內容資訊 英文 152 Pages
價格
US $ 1200 PDF by E-mail (single user license)
US $ 1600 Hard Copy
US $ 1900 PDF by E-mail (Global Site license)


生物仿製藥市場報告及預測：美國市場（2011∼2020年） 是由出版商IMARC Group在2011年10月所出版的。 這份英文市場調查報告書包含152 Pages 價格從美金1200起跳。

簡介

雖生物仿製藥於2010年銷售已經達到5,700萬美金，離眾多分析師所期待之10億美金銷售仍有一大段距離。但小分子非專利藥不同，比起短程，本市場似乎仍較為適合長程發展。

本報告為，分析美國生物仿製藥市場，並匯整市場現況及品牌藥銷售、專利趨勢、競合產品、開發中生物仿製藥及今後銷售預測等，以下列摘要形式闡述。

第1章 市場定義、調查方式

第2章 實施概要

第3章 美國生物仿製藥市場環境

第4章 美國生物仿製藥市場：現況

  • 生物仿製藥生長激素至今表現不均
  • 生長激素之主要顧客層為小兒科
  • Omitrope與不便之給藥裝置同時上市
  • Omnitrope之處方模式
  • 累積上市後的安全數據顯示今後攝取量將可能增加

第5章 價格、銷售量、銷售

  • Omnitrope無法接受其他標竿表現指標之基準
  • 歐洲之ESA及GCSF生物仿製藥帶給美國市場光明展望
  • 各種生物製劑等級中生物仿製藥之銷售量減少
  • 各種生物製劑等級中生物仿製藥之價格下滑
  • 各種生物製劑等級中生物仿製藥之銷售降低

第6章 藥劑別現況及預測

  • 生長激素
  • 紅細胞生成刺激劑
  • 粒細胞集落刺激因子
  • 胰島素
  • 干擾素
  • TNFα、單株抗體（免疫、發炎）
  • 單株抗體（癌症）

第7章 適應症別現況及預測

  • 免疫、發炎
  • 糖尿病
  • 癌症
  • 血液疾病
  • 發育不全

第8章 競爭環境

  • 品牌製造商
  • 生物仿製藥製造商

第9章 美國法規

  • Biologics Price Competition and Innovation Act
  • 未解決之生物仿製藥問題
  • 影響生物製劑製造商商務策略之主要挑戰
    • 兼容性和可替代性
    • 數據獨占性
    • 專利訴訟

第10章 企業簡介

  • Teva Pharmaceutical Industries Ltd
  • Sandoz, Inc
  • Hospira, Inc
  • STADA Arzeimittel AG
  • Dr. Reddy's Laboratories Ltd
  • Celltrion, Inc
  • Bioexpress Therapeutics SA

圖表

目錄

Abstract

Report Description & Highlights

With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. This market, however, unlike small molecule generics, is expected to be more akin to a marathon than a sprint. IMARC Group, one of the world' s leading research and advisory firms, in its new report "Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)" finds that biosimilars in the US will soon represent a multi-billion dollar market as they would be posing stiff competition to as many as twenty biological molecules during 2011-2020.

Findings from the report suggest that the historical performance of Omnitrope cannot be taken as a benchmark to gauge the potential of pipeline biosimilars as market acceptance for each biosimilar class is expected to vary significantly from one another. The report expects that the competition between branded biological drugs and their biosimilar counterparts would be more of a brand-brand competition than a brand-generic competition. The high costs involved in the development and launch of biosimilars are expected to limit the number of players in this market. As a result, erosions in price and volume caused by biosimilars are likely to be lower compared to those created by small molecule generics.

IMARC' s new report entitled "Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)" provides an analytical and statistical insight into the US biosimilar market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of six aspects of the US biosimilar market.

Key Aspects Analyzed:

Evaluating the Current Market Landscape of Biosimilars:

  • Identification of currently marketed biosimilars and their historical performance
  • Identifying the reasons for the slow uptake of currently marketed biosimilars
  • Analyzing historical data to formulate conclusions on the future growth and market trends of biosimilars

Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:

  • Analyzing historical time series data on price, volume and sales erosion in the US & Europe
  • Analyzing previous models and assumptions on price and volume erosion caused by biosimilars
  • Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by small molecule generics
  • Evaluating and comparing price, volume and sales erosion by biosimilars across various biological classes

Evaluating the Market Potential of Biosimilars Across Various Molecules:

Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa (Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) and Natalizumab (Tysabri).

Focus of the Analysis for Each Molecule:

  • Historical background and overview
  • Historical brand sales
  • Patent position
  • Competing products
  • Biosimilars in pipeline
  • Brand and biosimilar sales forecasts

Evaluating the Sales of Biosimilars across Various Indications:

Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency

Focus of the Analysis for Each Indication:

  • Historical brand sales
  • Brand and biosimilar sales forecasts
  • Indication wise breakup of molecules

Evaluating the Biosimilar Competitive Landscape:

  • Identifying branded biological manufacturers that expect the highest amount of erosion from biosimilars
  • Identifying biosimilar manufacturers and their pipelines

Understanding the Current Legislation on Biosimilars:

  • An insight into the Biologics Price Competition and Innovation Act
  • An insight into the key biosimilar issues that still remain unaddressed
  • Interchangeability and Substitutability
  • Data Exclusivity
  • Statutory provisions for dealing with patent litigations

Table of Contents

1 Market Definitions & Research Methodology

2 Executive Summary

3 The US Biosimilar Market Landscape

4 US Biosimilar Market: Current Experience

  • 4.1 The Performance of Growth Hormone Biosimilars Has Been Dismal So Far
  • 4.2 Pediatrics Represent the Prime Customer Base for Growth Hormones
  • 4.3 Omnitrope Was Launched with an Inconvenient Delivery Device
  • 4.4 Prescribing Patterns for Omnitrope
  • 4.5 Uptake is Likely to Increase with the Accumulation of Post-Market Safety Data

5 US Biosimlar Market: How Much Price, Volume & Sales Erosion will Result

  • 5.1 Omnitrope Cannot be Taken as a Benchmark to Gauge the Performance of Other Biosimilars
  • 5.2 The European Uptake of ESA & GCSF Biosimilars Give Us a Very Positive Outlook for the US
  • 5.3 Models for Biosimilar Volume Erosion Across Various Biological Classes
  • 5.4 Models for Biosimilar Price Erosion Across Various Biological Classes
  • 5.5 Models for Biosimilar Sales Erosion Across Various Biological Classes

6 US Biosimilar Market: Current Trends & Forecast by Drug

  • 6.1 Growth Hormones
    • 6.1.1 Somatropin (Genotropin/Humatrope/Other HGH)
      • 6.1.1.1 Drug Overview
      • 6.1.1.2 Current Brand & Biosimilar Sales
      • 6.1.1.3 Brand & Biosimilar Forecast (2011-2020)
  • 6.2 Erythropoiesis Stimulating Agents
    • 6.2.1 Epoetin Alfa (Epogen/Eprex)
      • 6.2.1.1 Drug Overview
      • 6.2.1.2 Historical Brand Sales
      • 6.2.1.3 Brand & Biosimilar Forecast (2011-2020)
  • 6.3 Granulocyte Colony Stimulating Factor
    • 6.3.1 Filgrastim (Neupogen)
      • 6.3.1.1 Drug Overview
      • 6.3.1.2 Historical Brand Sales
      • 6.3.1.3 Brand & Biosimilar Forecast (2011-2020)
    • 6.3.2 Pegfilgrastim (Neulasta)
      • 6.3.2.1 Drug Overview
      • 6.3.2.2 Historical Brand Sales
      • 6.3.2.3 Brand & Biosimilar Forecast (2011-2020)
  • 6.4 Insulin
    • 6.4.1 Insulin Lispro (Humalog)
      • 6.4.1.1 Drug Overview
      • 6.4.1.2 Historical Brand Sales
      • 6.4.1.3 Brand & Biosimilar Forecast (2011-2020)
    • 6.4.2 Insulin Glargine (Lantus)
      • 6.4.2.1 Drug Overview
      • 6.4.2.2 Historical Brand Sales
      • 6.4.2.3 Brand & Biosimilar Forecast (2011-2020)
    • 6.4.3 Insulin Detemir (Levemir)
      • 6.4.3.1 Drug Overview
      • 6.4.3.2 Historical Brand Sales
      • 6.4.3.3 Brand & Biosimilar Forecast (2011-2020)
  • 6.5 Interferons
    • 6.5.1 Interferon Beta-1A (Avonex)
      • 6.5.1.1 Drug Overview
      • 6.5.1.2 Historical Brand Sales
      • 6.5.1.3 Brand & Biosimilar Forecast (2011-2020)
    • 6.5.2 Interferon Beta-1A (Rebif)
      • 6.5.2.1 Drug Overview
      • 6.5.2.2 Historical Biosimilar Sales
      • 6.5.2.3 Brand & Biosimilar Forecast (2011-2020)
    • 6.5.3 Interferon Beta-1B (Betaferon/Betaseron)
      • 6.5.3.1 Drug Overview
      • 6.5.3.2 Historical Brand Sales
      • 6.5.3.3 Brand & Biosimilar Forecast (2011-2020)
  • 6.6 TNF Alpha & Monoclonal Antibodies (Immunology & Inflammation)
    • 6.6.1 Etanercept (Enbrel)
      • 6.6.1.1 Drug Overview
      • 6.6.1.2 Historical Brand Sales
      • 6.6.1.3 Brand & Biosimilar Forecast (2011-2020)
    • 6.6.2 Infliximab (Remicade)
      • 6.6.2.1 Drug Overview
      • 6.6.2.2 Historical Brand Sales
      • 6.6.2.3 Brand & Biosimilar Forecast (2011-2020)
    • 6.6.3 Adalimumab (Humira)
      • 6.6.3.1 Drug Overview
      • 6.6.3.2 Historical Brand Sales
      • 6.6.3.3 Brand & Biosimilar Forecast (2011-2020)
    • 6.6.4 Ranibizumab (Lucentis)
      • 6.6.4.1 Drug Overview
      • 6.6.4.2 Historical Brand Sales
      • 6.6.4.3 Brand & Biosimilar Forecast (2011-2020)
    • 6.6.5 Omalizumab (Xolair)
      • 6.6.5.1 Drug Overview
      • 6.6.5.2 Historical Brand Sales
      • 6.6.5.3 Brand & Biosimilar Forecast (2011-2020)
    • 6.6.6 Natalizumab (Tysabri)
      • 6.6.6.1 Drug Overview
      • 6.6.6.2 Historical Brand Sales
      • 6.6.6.3 Brand & Biosimilar Forecast (2011-2020)
  • 6.7 Monoclonal Antibodies (Oncology)
    • 6.7.1 Bevacizumab (Avastin)
      • 6.7.1.1 Drug Overview
      • 6.7.1.2 Historical Brand Sales
      • 6.7.1.3 Brand & Biosimilar Forecast (2011-2020)
    • 6.7.2 Trastuzumab (Herceptin)
      • 6.7.2.1 Drug Overview
      • 6.7.2.2 Historical Biosimilar Sales
      • 6.7.2.3 Brand & Biosimilar Forecast (2011-2020)
    • 6.7.3 Rituximab (Mabthera)
      • 6.7.3.1 Drug Overview
      • 6.7.3.2 Historical Biosimilar Sales
      • 6.7.3.3 Brand & Biosimilar Forecast (2011-2020)
    • 6.7.4 Cetuximab (Erbitux)
      • 6.7.4.1 Drug Overview
      • 6.7.4.2 Historical Brand Sales
      • 6.7.4.3 Brand & Biosimilar Forecast (2011-2020)

7 US Biosimilar Market: Current Trends & Forecast by Indication

  • 7.1 Immunology & Inflammation
    • 7.1.1 Current Trends & Forecast
    • 7.1.2 Biosimilar Sales Breakup by Molecule
  • 7.2 Diabetes
    • 7.2.1 Current Trends & Forecast
    • 7.2.2 Biosimilar Sales Breakup by Molecule
  • 7.3 Oncology
    • 7.3.1 Current Trends & Forecast
    • 7.3.2 Biosimilar Sales Breakup by Molecule
  • 7.4 Blood Disorders
    • 7.4.1 Current Trends & Forecast
    • 7.4.2 Biosimilar Sales Breakup by Molecule
  • 7.5 Growth Deficiency
    • 7.5.1 Current Trends & Forecast
    • 7.5.2 Biosimilar Sales Breakup by Molecule

8 Competitive Landscape

  • 8.1 Branded Manufacturers: Companies Facing the Highest Amount of Biosimilar Erosion
  • 8.2 Biosimilar Manufacturers: Companies Gaining the Most From Biosimilar Launches

9 Biosimilar Legislation in the US

  • 9.1 The Biologics Price Competition and Innovation Act: An Insight
  • 9.2 Biosimilar Issues that Still Remain Unaddressed
  • 9.3 Major Issues Impacting the Business Strategies of Biological Companies
    • 9.3.1 Interchangeability & Substitutability
    • 9.3.2 Data Exclusivity
    • 9.3.3 Patent Litigation

10 Key Company Profiles

  • 10.1 Teva Pharmaceutical Industries Ltd
  • 10.2 Sandoz, Inc
  • 10.3 Hospira, Inc
  • 10.4 STADA Arzneimittel AG
  • 10.5 Dr. Reddy' s Laboratories Ltd
  • 10.6 Celltrion, Inc
  • 10.7 Bioexpress Therapeutics SA

List of Figures

  • Figure 1-1: Model Used to Forecast Brand and Biosimilar Sales
  • Figure 2-1: US: Executive Summary: Biosimilar Timeline: 2011-2020
  • Figure 3-1: US: Biosimilar Market (in Million US$), 2007-2010
  • Figure 3-2: US: Biosimilar Timeline: 2011-2020
  • Figure 3-3: US: Biosimilar Market Forecast (in Million US$), 2011-2020
  • Figure 4-1: US: Human Growth Hormone Market: Sales Share of Different Brands & Biosimilars (in %), 2007-2010
  • Figure 4-2: US: Human Growth Hormone Market: Brand & Biosimilar Patient Share (in %), 2007-2020
  • Figure 5-1: US, Germany, France, Italy, Spain & UK: Somatropin Biosimilars: Patient Share (in %), 2007-2010
  • Figure 5-2: Germany, France, Italy, Spain & UK: Epoetin Alfa Biosimilars: Patient Share (in %), 2007-2010
  • Figure 5-3: US: Percentage of Physicians Expected to Prescribe ESA Biosimilars After They Have Been Launched, (in %), 2010
  • Figure 5-4: Germany, France, Italy, Spain & UK: Filgrastim Biosimilars: Patient Share (in %), 2008-2010
  • Figure 5-5: Average Generic Volume Erosion of Molecules Based-on Complex Drug Characteristics, (in %)
  • Figure 5-6: Average Generic Volume Erosion Across Various Countries From Time Since First Generic Entry, (in %)
  • Figure 5-7: Average Generic Price Erosion of Molecules Based Upon Complex Drug Characteristics, (in %)
  • Figure 5-8: Average Generic Price Erosion Across Various Countries From Time Since First Generic Entry
  • Figure 5-9: Average Brand Price Erosion Across Various Countries From Time Since First Generic Entry
  • Figure 6-1: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Brand & Biosimilar Sales Share (in %), 2007-2010
  • Figure 6-2: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Share of Marketed Brands & Biosimilars %), 2007-2010
  • Figure 6-3: US: Somatropin (Genotropin/Humatrope/Other HGH) Market Forecast: Brand & Biosimilar Sales Share %), 2011-2020
  • Figure 6-4: US: Epoetin Alfa (Epogen/Eprex) Market: Share of Marketed Brands (in %), 2007-2010
  • Figure 6-5: US: Epoetin Alfa (Epogen/Eprex) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-6: US: Filgrastim (Neupogen) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-7: US: Pegfilgrastim (Neulasta) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-8: US: Insulin Lispro (Humalog) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-9: US: Insulin Glargine (Lantus) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-10: US: Insulin Detemir (Levemir) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-11: US: Interferon Beta-1A (Avonex) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-12: US: Interferon Beta-1A (Rebif) Market: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-13: US: Interferon Beta-1B (Betaferon/Betaseron) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-14: US: Etanercept (Enbrel) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-15: US: Infliximab (Remicade) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-16: US: Adalimumab (Humira) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-17: US: Ranibizumab (Lucentis) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-18 : US: Omalizumab (Xolair) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-19: US: Natalizumab (Tysabri) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-20: US: Bevacizumab (Avastin) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-21: US: Trastuzumab (Herceptin) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-22 : US: Rituximab (Mabthera) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 6-23: US: Cetuximab (Erbitux) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
  • Figure 7-1: US: Biosimilar Market Forecast: Share by Indication (in %), 2011-2020
  • Figure 7-2: US: Immunology & Inflammation Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
  • Figure 7-3: US: Immunology & Inflammation Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
  • Figure 7-4: US: Diabetes Market forecast: Brand & Biosimilar Share (in %), 2011-2020
  • Figure 7-5: US: Diabetes Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
  • Figure 7-6: US: Oncology Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
  • Figure 7-7: US: Oncology Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
  • Figure 7-8: US: Blood Disorder Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
  • Figure 7-9: US: Blood Disorder Biosimilar Market Forecast: Anemia & Neutropenia Sales (in %), 2011-2020
  • Figure 7-10: US: Blood Disorder Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
  • Figure 7-11: US: Growth Deficiency Market: Brand & Biosimilar Share (in %), 2007-2010
  • Figure 7-12: US: Growth Deficiency Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
  • Figure 8-1: US: Innovator Company Brand Sales That Face Biosimilar Sales Erosion (in Million US$), 2010 & 2020

List of Tables

  • Table 1-1: US Biosimilar/Follow-On Biologics Market: Market Definition & Overview
  • Table 2-1: US: Executive Summary: Major Biosimilar Launches
  • Table 2-2: US: Executive Summary: Biosimilar Sales Forecast by Molecule (in Million US$), 2011-2020
  • Table 2-3: US: Executive Summary: Biosimilar Sales Forecast by Indication (in Million US$), 2011-2020
  • Table 3-1: US: Patent Expiries and Biosimilar Launch
  • Table 5-1: Biosimilar Vulnerability of Various Biopharmaceutical Classes
  • Table 5-2: Germany, France, Italy, Spain & UK: Epoetin Alfa Biosimilars: Patient Share (in %), 2007-2010
  • Table 5-3: Germany, France, Italy, Spain & UK: Filgrastim Biosimilars: Patient Share (in %), 2008-2010
  • Table 5-4: US: Various Studies & Assumptions for Biosimilar Volume Erosion
  • Table 5-5: US, Germany and UK: Biosimilar Volume Penetration by Molecule After 3 years from Launch (in %)
  • Table 5-6: Various Studies & Assumptions for Biosimilar Price Erosion
  • Table 5-7: US, Germany and UK: Biosimilar Sales Penetration by Molecule After 3 years from Launch (in %)
  • Table 6-1: US: Biosimilar Sales by Molecule (in Million US$), 2007-2010
  • Table 6-2: US: Biosimilar Sales Forecast by Molecule (in Million US$), 2011-2020
  • Table 6-3: US: Biosimilar Share Forecast by Molecule (in %), 2011-2020
  • Table 6-4: US: Somatropin: Brand & Biosimilar Market Overview
  • Table 6-5: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Brand & Biosimilar Sales/Patient Share, 2007-2010
  • Table 6-6: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Sales of Marketed Brands & Biosimilars Million US$), 2007-2010
  • Table 6-7: US: Somatropin (Genotropin/Humatrope/Other HGH) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-8: US: Epoetin Alfa: Brand & Biosimilar Market Overview
  • Table 6-9: US: Epoetin Alfa (Epogen/Eprex) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-10: US: Epoetin Alfa (Epogen/Eprex) Market: Sales of Marketed Brands (in Million US$), 2007-2010
  • Table 6-11: US: Epoetin Alfa (Epogen/Eprex) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-12: US: Filgrastim: Brand & Biosimilar Market Overview
  • Table 6-13: US: Filgrastim (Neupogen) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-14: US: Filgrastim (Neupogen) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-15: US: Pegfilgrastim: Brand & Biosimilar Market Overview
  • Table 6-16: US: Pegfilgrastim (Neulasta) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-17: US: Pegfilgrastim (Neulasta) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-18: US: Insulin Lispro: Brand & Biosimilar Market Overview
  • Table 6-19: US: Insulin Lispro (Humalog) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-20: US: Insulin Lispro (Humalog) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-21: US: Insulin Glargine: Brand & Biosimilar Market Overview
  • Table 6-22: US: Insulin Glargine (Lantus) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-23: US: Insulin Glargine (Lantus) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-24: US: Insulin Detemir: Brand & Biosimilar Market Overview
  • Table 6-25: US: Insulin Detemir (Levemir) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-26: US: Insulin Detemir (Levemir) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-27: US: Interferon Beta-1A (Avonex): Brand & Biosimilar Market Overview
  • Table 6-28: US: Interferon Beta-1A (Avonex) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-29: US: Interferon Beta-1A (Avonex) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-30: US: Interferon Beta-1A (Rebif): Brand & Biosimilar Market Overview
  • Table 6-31: US: Interferon Beta-1A (Rebif) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-32: US: Interferon Beta-1A (Rebif) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-33: US: Interferon Beta-1B: Brand & Biosimilar Market Overview
  • Table 6-34: US: Interferon Beta-1B (Betaferon/Betaseron) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-35: US: Interferon Beta-1B (Betaferon/Betaseron) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-36: US: Etanercept: Brand & Biosimilar Market Overview
  • Table 6-37: US: Etanercept (Enbrel) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-38: US: Etanercept (Enbrel) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-39: US: Infliximab: Brand & Biosimilar Market Overview
  • Table 6-40: US: Infliximab (Remicade) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-41: US: Infliximab (Remicade) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-42: US: Adalimumab: Brand & Biosimilar Market Overview
  • Table 6-43: US: Adalimumab (Humira) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-44: US: Adalimumab (Humira) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-45: US: Ranibizumab: Brand & Biosimilar Market Overview
  • Table 6-46: US: Ranibizumab (Lucentis) Market: Brand Sales (in Million US$), 2007-2010
  • Table 6-47: US: Ranibizumab (Lucentis) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-48: US: Omalizumab: Brand & Biosimilar Market Overview
  • Table 6-49: US: Omalizumab (Xolair) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-50: US: Omalizumab (Xolair) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-51: US: Natalizumab: Brand & Biosimilar Market Overview
  • Table 6-52: US: Natalizumab (Tysabri) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-53: US: Natalizumab (Tysabri) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-54: US: Bevacizumab: Brand & Biosimilar Market Overview
  • Table 6-55: US: Bevacizumab (Avastin) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-56: US: Bevacizumab (Avastin) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-57: US: Trastuzumab: Brand & Biosimilar Market Overview
  • Table 6-58: US: Trastuzumab (Herceptin) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-59: US: Trastuzumab (Herceptin) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-60: US: Rituximab: Brand & Biosimilar Market Overview
  • Table 6-61: US: Rituximab (Mabthera) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-62: US: Rituximab (Mabthera) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 6-63: US: Cetuximab: Brand & Biosimilar Market Overview
  • Table 6-64: US: Cetuximab (Erbitux) Market: Brand Sales (in Millions US$), 2007-2010
  • Table 6-65: US: Cetuximab (Erbitux) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
  • Table 7-1: US: Biosimilars Market: Indications Assigned for Various Molecules
  • Table 7-2: US: Biosimilars Market: Sales by Indication (in Million US$), 2007-2010
  • Table 7-3: US: Biosimilar Market Forecast: Sales by Indication (in Million US$), 2011-2020
  • Table 7-4: US: Immunology & Inflammation Market: Brand Sales (in Million US$), 2007-2010
  • Table 7-5: US: Immunology & Inflammation Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
  • Table 7-6: US: Immunology & Inflammation Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
  • Table 7-7: US: Diabetes Market: Brand Sales (in Million US$), 2007-2010
  • Table 7-8: US: Diabetes Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
  • Table 7-9: US: Diabetes Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
  • Table 7-10: US: Oncology Market: Brand Sales (in Million US$), 2007-2010
  • Table 7-11: US: Oncology Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
  • Table 7-12: US: Oncology Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
  • Table 7-13 : US: Blood Disorder Market: Brand Sales (in Million US$), 2007-2010
  • Table 7-14 : US: Blood Disorder Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
  • Table 7-15 : US: Blood Disorder Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
  • Table 7-16 : US: Growth Deficiency Market: Brand & Biosimilar Sales (in Million US$), 2007-2010
  • Table 7-17 : US: Growth Deficiency Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
  • Table 8-1: US: Innovator Companies Facing the Highest Amount of Biosimilar Sales Erosion (in Million US$), 2010, 2013, 2016 & 2020
  • Table 8-2: Companies Developing Herceptin (Trastuzumab) Biosimilars
  • Table 8-3: Companies Developing Enbrel (Etanercept) Biosimilars
  • Table 8-4: Companies Developing Remicade (Infliximab) Biosimilars
  • Table 8-5: Companies Developing Mabthera (Rituximab) Biosimilars
  • Table 8-6: Companies Developing Humira (Trastuzumab) Biosimilars
  • Table 8-7: Companies Developing Other Biosimilars
  • Table 9-1: US: Overview of Biosimilar Legislations
  • Table 9-2: Comparison of Patent Protection and Data Exclusivity
Back to Top